Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Victor Ochoa

Cardiovascular Disease Sacramento, CA Medical Doctor

NPI 1184878142 CMS profile 99629

500 University Ave., Ste 220, Sacramento, CA 95825

Open in the dashboard

General payments

$10,948

452 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Victor Ochoa of Sacramento, CA is reported in the CMS Open Payments database as having received $10,948 across 452 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,434 70
2024 General $753 48
2023 General $2,239 63
2022 General $424 24
2021 General $1,219 45
2020 General $689 35
2019 General $4,190 167

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Victor Ochoa
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Victor Ochoa were reported at $1,434. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Victor Ochoa Cardiovascular Disease median Middle half National median
2019 $4,190 $450 $127–$1,392 $163
2020 $689 $242 $77–$751 $114
2021 $1,219 $335 $101–$1,037 $132
2022 $424 $395 $121–$1,211 $149
2023 $2,239 $443 $136–$1,283 $160
2024 $753 $450 $136–$1,323 $164
2025 $1,434 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $4,634 193 payments
  2. Medtronic Vascular, Inc. $3,585 124 payments
  3. Abbott Laboratories $863 28 payments
  4. Amgen Inc. $409 13 payments
  5. Novartis Pharmaceuticals Corporation $293 21 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $194 21 payments
  7. Janssen Pharmaceuticals, Inc $190 11 payments
  8. Sanofi-Aventis U.S. LLC $125 1 payment
  9. AstraZeneca Pharmaceuticals LP $114 7 payments
  10. Regeneron Healthcare Solutions, Inc. $113 10 payments
  11. Other $429 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,623 418 payments
  2. Travel and Lodging $2,197 16 payments
  3. Education $127 18 payments
Products named General payments · program years 2019–2025
  1. Micra Pacemakers $1,484 38 payments
  2. Performa $1,041 15 payments
  3. Attain $982 7 payments
  4. AZURE XT DR MRI SURESCAN $939 92 payments
  5. AURORA EV-ICD MRI SURESCAN $493 3 payments
  6. SelectSecure $473 3 payments
  7. Claria MRI $452 18 payments
  8. Azure $425 30 payments
  9. Repatha $383 12 payments
  10. MICRA Pacemakers $331 19 payments
  11. Other $3,352 209 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 53 drugs

Part D claims

4,774

Median for Cardiology: 2,533

Drug cost

$1,079,875

Median for Cardiology: $485,213

Branded share of claims

31.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 638 $652,953
Entresto Sacubitril/Valsartan Brand 158 $142,732
Xarelto Rivaroxaban Brand 120 $130,278
Jardiance Empagliflozin Brand 73 $49,622
Repatha Sureclick Evolocumab Brand 49 $34,295
Metoprolol Succinate Generic 517 $7,910
Praluent Pen Alirocumab Brand 12 $5,882
Flecainide Acetate Generic 125 $5,864
Amiodarone Hcl Generic 82 $4,922
Atorvastatin Calcium Generic 496 $4,508

The 10 drugs with the highest cost, of 53 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$541,908

Of which drugs: $1,386

Medicare patients

1,250

Average age 76

Services billed

7,096

571 women, 679 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Ischemic heart disease 39%
Atrial fibrillation 38%
Diabetes 31%
Heart failure 29%
Chronic kidney disease 26%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 80 320 $996
Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) J0153 Office 18 828 $390

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

452 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record